15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.

      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Male, Adult, Aged, BCG Vaccine, adverse effects, therapeutic use, Carcinoma, Transitional Cell, drug therapy, Hepatitis, etiology, Humans, Immunotherapy, Middle Aged, Mycobacterium Infections, microbiology, Mycobacterium bovis, Pneumonia, Urinary Bladder Neoplasms

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Intravesical instillation of bacille Calmette-Guérin (BCG) effectively treats transitional cell carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some patients, infection appears early (within 3 months after instillation) and is characterized by generalized symptoms, with pneumonitis and hepatitis. Late-presentation disease occurs >1 year after the first BCG treatment and usually involves focal infection of the genitourinary tract (the site at which bacteria were introduced) and/or other sites that are typical for reactivation of mycobacterial disease, such as the vertebral spine or the retroperitoneal tissues. Noncaseating granulomas are found in the majority of cases, whether early or late. Most patients respond to treatment with antituberculous drugs; in early-presentation disease, when features of hypersensitivity predominate, glucocorticosteroids are sometimes added. Late localized infection often requires surgical resection.

          Related collections

          Author and article information

          Comments

          Comment on this article